McNeilly Tom N, Baker Alison, Brown Jeremy K, Collie David, Maclachlan Gerry, Rhind Susan M, Harkiss Gordon D
Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik EH26 0PZ, United Kingdom.
J Virol. 2008 Feb;82(3):1526-36. doi: 10.1128/JVI.02148-07. Epub 2007 Nov 28.
A major route of transmission of Visna/maedi virus (VMV), an ovine lentivirus, is thought to be via the respiratory tract, by inhalation of either cell-free or cell-associated virus. In previous studies, we have shown that infection via the lower respiratory tract is much more efficient than via upper respiratory tissues (T. N. McNeilly, P. Tennant, L. Lujan, M. Perez, and G. D. Harkiss, J. Gen. Virol. 88:670-679, 2007). Alveolar macrophages (AMs) are prime candidates for the initial uptake of virus in the lower lung, given their in vivo tropism for VMV, abundant numbers, location within the airways, and role in VMV-induced inflammation. Furthermore, AMs are the most likely cell type involved in the transmission of cell-associated virus. In this study, we use an experimental in vivo infection model that allowed the infection of specific segments of the ovine lung. We demonstrate that resident AMs are capable of VMV uptake in vivo and that this infection is associated with a specific up-regulation of AM granulocyte-macrophage colony-stimulating factor mRNA expression (P < 0.05) and an increase in bronchoalveolar lymphocyte numbers (P < 0.05), but not a generalized inflammatory response 7 days postinfection. We also demonstrate that both autologous and heterologous VMV-infected AMs are capable of transmitting virus after lower, but not upper, respiratory tract instillation and that this transfer of virus appears not to involve the direct migration of virus-infected AMs from the airspace. These results suggest that virus is transferred from AMs into the body via an intermediate route. The results also suggest that the inhalation of infected AMs represents an additional mechanism of virus transmission.
维士那/梅迪病毒(VMV)是一种绵羊慢病毒,其主要传播途径被认为是通过呼吸道,吸入无细胞病毒或细胞相关病毒。在先前的研究中,我们已经表明,经下呼吸道感染比经上呼吸道组织感染更有效(T.N.麦克尼尔、P.坦南特、L.卢扬、M.佩雷斯和G.D.哈基斯,《普通病毒学杂志》88:670 - 679,2007年)。肺泡巨噬细胞(AMs)是下肺中病毒初始摄取的主要候选细胞,考虑到它们在体内对VMV的嗜性、数量丰富、位于气道内以及在VMV诱导的炎症中的作用。此外,AMs是参与细胞相关病毒传播的最可能的细胞类型。在本研究中,我们使用了一种实验性体内感染模型,该模型允许感染绵羊肺的特定节段。我们证明驻留的AMs能够在体内摄取VMV,并且这种感染与AMs粒细胞 - 巨噬细胞集落刺激因子mRNA表达的特异性上调(P < 0.05)以及支气管肺泡淋巴细胞数量的增加(P < 0.05)相关,但在感染后7天没有全身性炎症反应。我们还证明,自体和异源VMV感染的AMs在下呼吸道而非上呼吸道滴注后能够传播病毒,并且这种病毒转移似乎不涉及病毒感染的AMs从气腔的直接迁移。这些结果表明病毒通过中间途径从AMs转移到体内。结果还表明,吸入受感染的AMs代表了病毒传播的另一种机制。